Organon & Co.

OGN Healthcare Drug Manufacturers General

Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024. In the quarter to June 2026, revenue fell 2.26%, EPS fell 26.8%, free cash flow fell 83.0% and total debt fell 3.86%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

13.76 0.00 0.00%
Market cap
$3.6B
P/E
17.4×
Fwd P/E
5.2×
Dividend yield
0.58%
F-score
5/9
Altman Z
1.09
Beneish M
−2.68
Dividend safety
45/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

5 5 5 5
ROE
71.62% 30.56% 34.05% 24.04%
ROA
3.81% 1.44% 1.88% 1.57%
ROIC
8.30% 5.84% 6.18% 6.11%
Return on Tangible Assets
15.13% 5.73% 6.63% 5.53%
Average Days of Receivables
85.96 78.16 81.97 88.88
Free Cash Flow per Share
2.40 1.60 2.63 1.77
Free Cash Flow
624.00 415.00 684.00 464.00
Other line items

Show all line items

Columns are period end dates